MDGL Stock Forecast 2025-2026
Distance to MDGL Price Targets
MDGL Price Momentum
10 Quality Stocks Worth Considering Now
Researching Madrigal Pharmaceuticals (MDGL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MDGL and similar high-potential opportunities.
Latest MDGL Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, MDGL has a bullish consensus with a median price target of $405.00 (ranging from $239.00 to $539.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $333.82, the median forecast implies a 21.3% upside. This outlook is supported by 14 Buy, 1 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDGL Analyst Ratings
MDGL Price Target Range
Latest MDGL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDGL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $405.00 |
| Feb 27, 2025 | Citigroup | David Lebovitz | Buy | Maintains | $469.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $400.00 |
| Jan 10, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $427.00 |
| Nov 20, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Neutral | Reiterates | $0.00 |
| Nov 5, 2024 | B. Riley Securities | Mayank Mamtani | Neutral | Maintains | $236.00 |
| Nov 1, 2024 | UBS | Eliana Merle | Buy | Maintains | $441.00 |
| Oct 23, 2024 | Oppenheimer | Jay Olson | Outperform | Maintains | $350.00 |
| Oct 22, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $390.00 |
| Oct 11, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Neutral | Reiterates | $0.00 |
| Aug 8, 2024 | Citigroup | David Lebovitz | Buy | Maintains | $371.00 |
| Aug 8, 2024 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $360.00 |
| Jul 23, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Neutral | Reiterates | $0.00 |
| Jul 16, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $385.00 |
| Jun 28, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Neutral | Initiates | $0.00 |
| Jun 11, 2024 | Wolfe Research | Andy Chen | Outperform | Initiates | $0.00 |
| May 10, 2024 | B. Riley Securities | Mayank Mamtani | Neutral | Maintains | $200.00 |
| May 8, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $381.00 |
| May 8, 2024 | Citigroup | David Lebovitz | Buy | Maintains | $382.00 |
| May 8, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $390.00 |
Madrigal Pharmaceuticals Inc. (MDGL) Competitors
The following stocks are similar to Madrigal Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Madrigal Pharmaceuticals Inc. (MDGL) Financial Data
Madrigal Pharmaceuticals Inc. has a market capitalization of $7.37B with a P/E ratio of -15.2x. The company generates $180.13M in trailing twelve-month revenue with a -258.6% profit margin.
Revenue growth is +66.2% quarter-over-quarter, while maintaining an operating margin of -64.8% and return on equity of -80.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Madrigal Pharmaceuticals Inc. (MDGL) Business Model
About Madrigal Pharmaceuticals Inc.
Develops therapies for cardiovascular and metabolic diseases.
Madrigal Pharmaceuticals operates as a clinical-stage biopharmaceutical company, primarily focusing on the development of innovative therapies for significant unmet medical needs. The company generates revenue through the commercialization of its lead product candidate, resmetirom, which targets Non-Alcoholic Steatohepatitis (NASH) and potential cardiovascular disorders.
The firm is dedicated to advancing health solutions and improving patient outcomes through scientific excellence and innovative research. Madrigal's role in the pharmaceutical industry is critical, particularly in addressing diseases related to metabolic disorders, which have substantial impacts on healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
528
CEO
Mr. William J. Sibold
Country
United States
IPO Year
2007
Website
www.madrigalpharma.comMadrigal Pharmaceuticals Inc. (MDGL) Latest News & Analysis
Madrigal Appoints Jacqualyn A. Fouse, Ph.D.
16 days agoFred Craves, Ph.D. will retire from Madrigal's Board of Directors in July 2025, as announced by the company.
Fred Craves' retirement from Madrigal's Board could lead to shifts in strategic direction and governance, impacting investor confidence and the company's future performance.
Madrigal Pharmaceuticals reported $103.3M in Q4 sales for Rezdiffra, but faces competition from GLP-1 drugs. A Phase 3 trial aims for label expansion by 2027, with EMA approval expected mid-2025.
Madrigal's strong Rezdiffra sales boost confidence, but competition from GLP-1 drugs poses risks. Future trial outcomes and EMA approval will be crucial for maintaining market position.
Madrigal Pharmaceuticals CEO Bill Sibold discussed the company's quarterly results during an appearance on 'Fast Money.'
Madrigal Pharmaceuticals' CEO discussing quarterly results may impact stock performance, revealing insights on financial health and future growth potential, influencing investor sentiment.
Madrigal Pharmaceuticals (MDGL) shares rose 15.2% by 11:05 a.m. ET on Wednesday.
Madrigal Pharmaceuticals' significant share increase signals positive market sentiment, potentially driven by favorable news or developments, which could attract more investor interest and boost trading volume.
Madrigal Pharmaceuticals, Inc. (MDGL) has released its Q4 2024 earnings call transcript, providing insights into the company's financial performance and strategic updates.
Madrigal Pharmaceuticals' Q4 earnings call provides insights into financial performance, growth prospects, and strategic direction, impacting stock valuation and investor sentiment.
Madrigal Pharmaceuticals' Rezdiffra saw Q4 sales rise 66% to $103.3M. Despite a $466M net loss in 2024, cash reserves reached $931M. Upcoming European approval may enhance market position.
Madrigal's strong sales growth for Rezdiffra and improved cash position highlight financial resilience. Its unique market position and potential European approval could attract acquisition interest.
Frequently Asked Questions About MDGL Stock
What is Madrigal Pharmaceuticals Inc.'s (MDGL) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Madrigal Pharmaceuticals Inc. (MDGL) has a median price target of $405.00. The highest price target is $539.00 and the lowest is $239.00.
Is MDGL stock a good investment in 2025?
According to current analyst ratings, MDGL has 14 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $333.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDGL stock?
Wall Street analysts predict MDGL stock could reach $405.00 in the next 12 months. This represents a 21.3% increase from the current price of $333.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Madrigal Pharmaceuticals Inc.'s business model?
Madrigal Pharmaceuticals operates as a clinical-stage biopharmaceutical company, primarily focusing on the development of innovative therapies for significant unmet medical needs. The company generates revenue through the commercialization of its lead product candidate, resmetirom, which targets Non-Alcoholic Steatohepatitis (NASH) and potential cardiovascular disorders.
What is the highest forecasted price for MDGL Madrigal Pharmaceuticals Inc.?
The highest price target for MDGL is $539.00 from at , which represents a 61.5% increase from the current price of $333.82.
What is the lowest forecasted price for MDGL Madrigal Pharmaceuticals Inc.?
The lowest price target for MDGL is $239.00 from at , which represents a -28.4% decrease from the current price of $333.82.
What is the overall MDGL consensus from analysts for Madrigal Pharmaceuticals Inc.?
The overall analyst consensus for MDGL is bullish. Out of 19 Wall Street analysts, 14 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $405.00.
How accurate are MDGL stock price projections?
Stock price projections, including those for Madrigal Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
